Prognostic implications of EGFR and HER-2 alteration assessed by immunohistochemistry and silver in situ hybridization in gastric cancer patients following curative resection

被引:47
作者
Oh, Ho Suk [1 ]
Eom, Dae-Woon [2 ]
Kang, Gil Hyun [2 ]
Ahn, Yong Chel [1 ]
Lee, Sang Jin [1 ]
Kim, Ji-Hoon [3 ]
Jang, Hyuk Jai [3 ]
Kim, Eun Jung [1 ]
Oh, Kwang Hoon [1 ]
Ahn, Heui June [1 ]
机构
[1] Univ Ulsan, Coll Med, GangNeung Asan Med Ctr, Dept Internal Med, Kangnung 210711, Gangwon Do, South Korea
[2] Univ Ulsan, Coll Med, GangNeung Asan Med Ctr, Dept Pathol, Kangnung 210711, Gangwon Do, South Korea
[3] Univ Ulsan, Coll Med, GangNeung Asan Med Ctr, Dept Surg, Kangnung 210711, Gangwon Do, South Korea
关键词
Gastric cancer; EGFR; HER-2; Prognosis; SISH; IHC; GROWTH-FACTOR RECEPTOR; LYMPH-NODE DISSECTION; GENE AMPLIFICATION; TUMOR PROGRESSION; POOR-PROGNOSIS; EXPRESSION; 5-FLUOROURACIL; CHEMOTHERAPY; CARCINOMAS; SURVIVAL;
D O I
10.1007/s10120-013-0288-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
The aim of this study was to use immunohistochemistry (IHC) and silver in situ hybridization (SISH) to evaluate alterations in EGFR and HER2 in gastric cancer in order to determine the relationship with prognosis in gastric cancer patients following curative resection. In this study, we analyzed EGFR and HER-2 status by IHC and SISH in 254 stage I-III gastric cancer patients who underwent curative surgery. Thirteen cases (2.48 %) showed EGFR alteration by IHC or SISH. EGFR alteration was associated with older age (P = 0.021), intestinal type (P = 0.040) and higher stage disease (P < 0.001). The patients with operable state gastric cancer who had EGFR alteration had an unfavorable prognosis, and multivariate analysis confirmed that EGFR alteration was an independent unfavorable prognostic factor. Twenty-seven cases (10.6 %) showed HER-2 alteration by IHC or SISH. HER-2 alteration was associated with older age (P = 0.006), well or moderately differentiated histology (P < 0.001) and intestinal type (P = 0.002). HER-2 alteration is not an independent prognostic factor for curatively resectable gastric cancer. We observed EGFR alteration in a subset of cases with operable state gastric cancer and determined that it was associated with an unfavorable prognosis.
引用
收藏
页码:402 / 411
页数:10
相关论文
共 46 条
[1]
Bang YJ, 2010, LANCET, V376, P1302
[2]
Critical update and emerging trends in epidermal growth factor receptor targeting in cancer [J].
Baselga, J ;
Arteaga, CL .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) :2445-2459
[3]
Extended lymph-node dissection for gastric cancer [J].
Bonenkamp, JJ ;
Hermans, J ;
Sasako, M ;
van de Velde, CJH .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (12) :908-914
[4]
Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial [J].
Cascinu, Stefano ;
Labianca, Roberto ;
Barone, Carlo ;
Santoro, Armando ;
Carnaghi, Carlo ;
Cassano, Alessandra ;
Beretta, Giordano D. ;
Catalano, Vincenzo ;
Bertetto, Oscar ;
Barni, Sandro ;
Frontini, Luciano ;
Aitini, Enrico ;
Rota, Silvia ;
Torri, Valter ;
Floriani, Irene .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (08) :601-607
[5]
A phase III randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil and mitomycin C versus 5-fluorouracil alone in curatively resected gastric cancer [J].
Chang, HM ;
Jung, KH ;
Kim, TY ;
Kim, WS ;
Yang, HK ;
Lee, KU ;
Choe, KJ ;
Heo, DS ;
Bang, YJ ;
Kim, NK .
ANNALS OF ONCOLOGY, 2002, 13 (11) :1779-1785
[6]
Gastrointestinal cancer: recent developments in medical oncology [J].
Chong, G ;
Cunningham, D .
EJSO, 2005, 31 (05) :453-460
[7]
Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models [J].
Fujimoto-Ouchi, Kaori ;
Sekiguchi, Fumiko ;
Yasuno, Hideyuki ;
Moriya, Yoichiro ;
Mori, Kazushige ;
Tanaka, Yutaka .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 59 (06) :795-805
[8]
Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery [J].
Galizia, Gennaro ;
Lieto, Eva ;
Orditura, Michele ;
Castellano, Paolo ;
La Mura, Anna ;
Imperatore, Vincenzo ;
Pinto, Margherita ;
Zamboli, Anna ;
De Vita, Ferdinando ;
Ferraraccio, Francesca .
WORLD JOURNAL OF SURGERY, 2007, 31 (07) :1458-1468
[9]
Epidermal growth factor receptor expression correlates with poor survival in gastric adenocarcinoma from Mexican patients:: a multivariate analysis using a standardized immunlohistochemical detection system [J].
Gamboa-Dominguez, A ;
Dominguez-Fonseca, C ;
Quintanilla-Martinez, L ;
Reyes-Gutierrez, E ;
Green, D ;
Angeles-Angeles, A ;
Busch, R ;
Hermannstädter, C ;
Nährig, J ;
Becker, KF ;
Becker, I ;
Höfler, H ;
Fend, F ;
Luber, B .
MODERN PATHOLOGY, 2004, 17 (05) :579-587
[10]
Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer [J].
García, I ;
Vizoso, F ;
Martín, A ;
Sanz, L ;
Abdel-Lah, O ;
Raigoso, P ;
García-Muñiz, JL .
ANNALS OF SURGICAL ONCOLOGY, 2003, 10 (03) :234-241